Yuhao Zhang
张玉豪
Yuhao Zhang is an investor at Source Code Capital, where he focuses on life sciences and AI-for-science bets. He was the first investor in DeepWise (深势科技), an AI4S company, and later led Source Code's investment in the company's Series B . He also led the Pre-B round in Saiqiao Biotech (赛桥生物), a cell-and-gene-therapy tools maker , and has backed Sainuo Biology and Starna Therapeutics . Elsewhere's corpus does not cover his background before Source Code Capital.
AI-generated — may contain errors, please verify.
Coverage
MaKe | MaHui Member CytoBridge Bio Closes Nearly RMB 200 Million Series B Round; Source Code Capital Led Pre-B Round
MaKe | Multiple MaHui Members Named to 2023 China Healthcare Industry Investment and Financing Glory List
CodeMark | Minghao Technology Announces Completion of Tens of Millions of RMB in Series A Funding, Led by Source Code Capital
J&T Global Express will accelerate the marketization of visual health outcomes.
Qiheshengke Biotechnology Raises Over 100 Million RMB in Pre-A Round with Source Code Capital Participation
This round of funding will help Qiheshengke Biotechnology accelerate the commercialization of gene-edited bio-breeding.
Source Code Capital | "Sainuo Biology" Completes Hundreds of Millions of RMB in Series C+ Funding, Led by Source Code Capital
With this round of capital, Sainuo Bio will stay true to its founding mission, leverage its team's proprietary R&D strengths, actively refine its product portfolio, and vigorously advance its commercialization efforts.
MaHui | Multiple MaHui Members Win Awards at HICOOL 2022 Global Entrepreneurship Competition
MaHui Entrepreneurs | AI4S Industrialization Roundtable: With So Many Application Scenarios, "AI Tools" Will Deliver Greater Value
MaHui Entrepreneurs | Two 29-Year-Old Genius Scientists and Their "Moon and Sixpence"
Code Moment | "Starna Therapeutics" Announces 150 Million Yuan Series A Funding Round, Source Code Capital Participates
Focus on extrahepatic delivery to build a core platform with global competitiveness.
"The Tech + Biotech" Crossover: A New Investment Consensus on Convergent Innovation
Professional, systematic, and patient for the long haul.
